C Salliot

Summary

Publications

  1. pmc Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
  2. pmc Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:25-32. 2009
  3. doi request reprint Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases
    E Régnier-Rosencher
    Department of Dermatology, Hopital Cochin, APHP, Universite Rene Descartes Paris V, Paris, France
    Dermatology 224:72-83. 2012
  4. doi request reprint Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients
    L Gossec
    Paris Descartes University and AP HP, Cochin Hospital, Paris, France
    Arthritis Care Res (Hoboken) 65:712-7. 2013
  5. ncbi request reprint Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen-Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007

Collaborators

Detail Information

Publications5

  1. pmc Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research
    C Salliot
    Paris Descartes University, Medicine Faculty, Rheumatology B Department, Cochin Hospital, Paris, France
    Ann Rheum Dis 68:1100-4. 2009
    ..To perform a systematic literature review of the long-term safety of methotrexate (MTX) monotherapy in rheumatoid arthritis (RA)...
  2. pmc Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials
    C Salliot
    Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Ann Rheum Dis 68:25-32. 2009
    ..Recently, new biological agents have become available. Their safety is an important issue...
  3. doi request reprint Factors associated with severe skin infections in patients treated with biologic therapies for inflammatory rheumatic diseases
    E Régnier-Rosencher
    Department of Dermatology, Hopital Cochin, APHP, Universite Rene Descartes Paris V, Paris, France
    Dermatology 224:72-83. 2012
    ..The incidence of severe infections is increased under biologic therapies and the skin is the second localization...
  4. doi request reprint Challenges of cardiovascular risk assessment in the routine rheumatology outpatient setting: an observational study of 110 rheumatoid arthritis patients
    L Gossec
    Paris Descartes University and AP HP, Cochin Hospital, Paris, France
    Arthritis Care Res (Hoboken) 65:712-7. 2013
    ..The objective was to assess the feasibility and usefulness of a standardized CV risk assessment in RA, performed by rheumatologists during outpatient clinics...
  5. ncbi request reprint Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers
    A Ruyssen-Witrand
    Paris Rene Descartes University, Medicine Faculty, AP HP, Cochin Hospital, Rheumatology B Department, Paris, France
    Clin Exp Rheumatol 25:430-6. 2007
    ..The aim of this study was to assess the complication rate after surgery in such patients, to assess the effect of interrupting TNF blocker therapy, and to identify other potential predictors of complications...